Pinobio Accelerates Global Clinical Trials for Ovarian and Bladder Cancer Treatments... "Patient Dosing Begins in Australian Trials"

[Asia Economy Reporter Hyunseok Yoo] Pinobio announced on the 2nd that it has started patient dosing for the Australian combination therapy Phase 1/2 clinical trial of the targeted anticancer drug NTX-301. This clinical trial is being conducted with a total of 125 patients, targeting platinum-resistant ovarian cancer and bladder cancer.

NTX-301 is a nucleoside-class DNMT1 inhibitory targeted anticancer drug. According to the presentation at the American Society of Clinical Oncology (ASCO) in June, NTX-301 demonstrated excellent safety and efficacy in a U.S. monotherapy clinical trial involving solid tumor patients. It achieved a high Disease Control Rate (DCR) of 78.5% in patients with advanced solid tumors. Among the treated patients, one patient each with leiomyosarcoma and clear cell ovarian cancer showed stable disease (SD) lasting more than six months. Anticancer efficacy with SD lasting over four months was also confirmed in the very low dose group.

The Australian Phase 1/2 clinical trial is expected to be completed in 2023. Dooyoung Jung, CEO of Pinobio, stated, “The combination therapy effect of Decitabine, a commercialized drug with the same mechanism, and platinum-based anticancer agents has already been validated through existing clinical trials, so the possibility of success in the Australian combination therapy clinical development and commercialization of the best-in-class NTX-301 is very high.”

In addition to the Australian trial, Pinobio is conducting a U.S. Phase 1/2 clinical trial of NTX-301 for solid tumors and hematologic cancers, and a domestic Phase 1 clinical trial of NTX-101 for ischemic optic neuropathy ophthalmic disease. Furthermore, based on the next-generation antibody-drug conjugate (ADC) platform Pinot-ADCTM, the company is actively discovering ADC anticancer drug candidates and advancing its platform business.

This content was produced with the assistance of AI translation services.